Tuesday, March 29, 2022 10:16:23 AM
$RVVTF investors, are you bailing, standing pat or adding to positions after the missed timeline, which is prob procedural after moving the trial to 🇹🇷 (over 7/10ths complete). Also let us know in the comments whether you see potential off-label use upon approval for "Long Covid"
— TDR (@TheDalesReport) March 29, 2022
Ps. What do you think about the off label use for long covid mike?
Pps..time for work arrhh
https://twitter.com/danfaraci/status/1508812377906720773?t=psAp2fOTRhBzux4LaST2-w&s=19
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
